{"id":"W3107792394","doi":"10.1182/bloodadvances.2020003314","title":"Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Astex Pharmaceuticals; Jazz Pharmaceuticals; Medical Research Council; Celgene; Gilead Sciences; Alexion Pharmaceuticals; Astellas Pharma; TG Therapeutics; Pfizer; Agios Pharmaceuticals; Bristol-Myers Squibb","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Adverse effect; Anemia; Pharmacokinetics; Internal medicine; Randomized controlled trial; Pharmacodynamics; Gastroenterology; Bone marrow","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002951586,0.0005136918,0.001274052,0.0002350007,0.0002491912,0.0008352315,0.0006060402,0.001062154,0.002249014],"category_scores_gemma":[0.003857686,0.0002483468,0.0009816609,0.000315002,0.0003712476,0.000569382,0.0002328435,0.00260528,0.000500687],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007144787,"about_ca_system_score_gemma":0.0009277743,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005165504,"about_ca_topic_score_gemma":0.001490952,"domain_scores_codex":[0.9990663,0.0006217777,0.00005453077,0.0001021896,0.00009777067,0.00005738642],"domain_scores_gemma":[0.998529,0.0005484335,0.0003638088,0.00009532172,0.0001250908,0.0003384493],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7915889,0.008025089,0.008496595,0.0008884447,0.001646993,0.0001862635,0.0001661985,0.005094613,0.01442143,0.0006619471,0.01129676,0.1575268],"study_design_scores_gemma":[0.8605534,0.09598591,0.02636208,0.0001971149,0.001894782,0.0002849811,0.00006353763,0.004035186,0.002647016,0.001051452,0.006864954,0.00005953277],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9838456,0.004902363,0.0007768728,0.002657956,0.0001652795,0.001084349,0.001738575,0.0001171291,0.004711844],"genre_scores_gemma":[0.986388,0.002124497,0.002887186,0.002588894,0.0002327449,0.001184461,0.003497574,0.00003442817,0.001062423],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002951586,"threshold_uncertainty_score":0.01560968,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05893450828529068,"score_gpt":0.3189789532074175,"score_spread":0.2600444449221268,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}